Madam Chair and members of Parliament, this gives me an opportunity to talk about our methods.
The task force does the recommendations on different aspects of prevention and screening. The way we approach it is that we look comprehensively at all the data. We have looked at all data, old and new. All the newer observational studies are incorporated into our thinking about these recommendations. I don't know what more to say. We did look comprehensively at all the data, including data on the values and preferences of patients. We had more than 86 studies informing the values and preferences of patients on breast cancer screening, and it was clear—